Trial Profile
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Mar 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 03 Nov 2020 Results of a pooled analysis of data pooled from 6 randomized controlled trials assessing the relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis published in the International Journal of Clinical Pharmacology and Therapeutics
- 01 May 2018 Results published in The Journal of Rheumatology
- 10 Jul 2012 Results published in the Journal of Pain.